An interventional study of Training in Diabetes Mellitus, Type 2, sponsored by Morten Hostrup, PhD. Completed at 1 site in Denmark. Open to male participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-04-12.
Sponsored by Morten Hostrup, PhD · Not applicable, Interventional, and Basic science
Among 475 studies in Diabetes Mellitus, Type 2 with a site in Denmark — 44 open to participants now, 60 under way, 7 of them phase 3. Diabetes Mellitus, Type 2 · Denmark.
Among the 475 studies in Diabetes Mellitus, Type 2 with a site in Denmark, this one is the 217th largest by enrollment of the 377 interventional ones that give a count, is one of 23 that started in 2017, is one of 179 with no phase, and was the 312th registered.
10,371 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,406 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →44 of the 475 studies in Diabetes Mellitus, Type 2 with a site in Denmark are open now. Recruiting first, the newest first:
Odense University Hospital · Sites in Denmark
AstraZeneca · Sites in Denmark, United States, Argentina and 8 more countries
AstraZeneca · Sites in Denmark, United States, Argentina and 10 more countries
AstraZeneca · Sites in Denmark, United States, Argentina and 21 more countries
AstraZeneca · Sites in Denmark, United States, Bulgaria and 13 more countries
A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 373 (42%) set no upper age limit and 384 (43%) stop at 75 or younger; 52 take children under 18; 203 take healthy volunteers.
This study: 30 Years to 70 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
475 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 51 · Phase 3 88 · Phase 4 49
First in 1992; this study’s year is marked. 23 started in 2017.
This study's enrollment of 45 is below the median of 80 across 8,350 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 64 across the 377 interventional studies, 150 across the 97 observational. Of the 370 that completed or were terminated, 82 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
157 of 475 have an industry lead sponsor. The 10 most frequent:
Morten Hostrup, PhD is the lead sponsor of 17 studies on the registry; 7 are open to participants now.
Morten Hostrup, PhD has 2 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
15 of the studies in Diabetes Mellitus, Type 2 with a site in Denmark that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07482072Rigshospitalet, DenmarkBrain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study | 2026-12 |
| NCT07421024Morten Hostrup, PhDGRK-Biased Activation Via β2-Adrenergic Receptors in Human Skeletal Muscle | 2026-12-31 |
| NCT03620266Ole Frobert, MD, PhDEffects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI | 2026-12-31 |
| NCT05915260Slagelse HospitalCMR in T2DM: The NSR Cohort | 2026-12-31 |
| NCT07026539University of AarhusEffect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes. | 2026-12-31 |
Among the 475 studies in Diabetes Mellitus, Type 2 with a site in Denmark, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The project will investigate high intensity interval training on the glucose regulation in type 2 diabetic subjects compared to moderate continuous exercise.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Type 2 diabetes Age: 30-70 Non smokers (minimum the last 15 years) Inactive lifestyle (\<2 hours pr. week) \<35 kg/m2
Exclusion Criteria:
Smoking Prior cardiavascular diseases Alcohol intake 14> units pr. week.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Moderate continuous exercise three times pr. week for 50 min.
Behavioral: Training
High intensity interval training three times pr. week for 15 min.
Behavioral: Training
The duration of the training intervention is 10 weeks of either moderate exercise og high intensity interval training.
HbA1c
Long term blood glucose levels
Time frame: From baseline measure to post test: 10 weeks
Oral glucose tolerance test
75gr glucose is ingested, bllod sampling over the following two hours
Time frame: From baseline measure to post test: 10 weeks
Plan to share: Undecided
Ran from Aug 2017 to primary completion in Dec 2018, 16 months.
Of 2,066 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 16 months is below that.
Counting every sponsor, half of 2,243 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Morten Hostrup, PhD